OncoCyte Corporation (OCX)
NASDAQ: OCX · Real-Time Price · USD
2.770
-0.040 (-1.42%)
May 13, 2025, 4:00 PM - Market closed

OncoCyte Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
May '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Market Capitalization
79402138200161
Upgrade
Market Cap Growth
261.57%94.02%-45.76%-80.98%24.52%37.45%
Upgrade
Enterprise Value
52411414162159
Upgrade
Last Close Price
2.772.382.506.4243.4047.80
Upgrade
PS Ratio
9.4221.3013.7439.7491.06132.18
Upgrade
PB Ratio
7.75-3.260.810.963.074.80
Upgrade
P/TBV Ratio
-----17.31
Upgrade
EV/Sales Ratio
13.4421.649.6015.0773.75130.37
Upgrade
Debt / Equity Ratio
0.34-0.300.110.090.090.26
Upgrade
Debt / EBITDA Ratio
0.010.010.00---
Upgrade
Asset Turnover
0.060.030.020.010.020.03
Upgrade
Quick Ratio
3.571.411.381.852.500.89
Upgrade
Current Ratio
3.751.621.492.112.771.03
Upgrade
Return on Equity (ROE)
-428.96%-910.86%-76.26%-35.52%-88.37%-93.07%
Upgrade
Return on Assets (ROA)
-22.25%-26.42%-15.91%-13.88%-13.82%-42.66%
Upgrade
Return on Capital (ROIC)
-86.08%-146.37%-38.88%-31.60%-26.30%-51.52%
Upgrade
Earnings Yield
-73.80%-151.40%-134.52%-191.48%-32.03%-18.62%
Upgrade
FCF Yield
-29.71%-52.98%-114.30%-131.09%-19.08%-16.93%
Upgrade
Buyback Yield / Dilution
-112.14%-70.84%-38.10%-24.61%-35.80%-27.65%
Upgrade
Updated Mar 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q